Neuropsychiatric adverse side-effects of montelukast in children – a Danish nationwide register study.

Louise Toennesen, Alexander Jordan, Josefin Eklof, Pradeesh Sivapalan, Astrid Sevelsted, Klaus Bønnelykke, Charlotte Suppli Ulrik, Jens-ulrik Stæhr Jensen

Research output: Contribution to journalConference abstract in journalResearch

Abstract

Background: Leukotriene receptor antagonist including montelukast, may have neuropsychiatric adverse effects, but findings have been conflicting, also in paediatric patients.

Objective: To assess if montelukast exposure in children with asthma is associated with onset of neuropsychiatric adverse events using data from the Danish nationwide health registers.

Methods: Children aged 5-17 years with either ≥1 prescription redemption of inhaled corticosteroids or montelukast, or with at least one hospital contact with asthma between January 1, 2010 and December 31, 2018 were included.

Outcomes were: use of neuropsychiatric medicine (Outcome 1), and hospital contacts with a neuropsychiatric diagnosis (Outcome 2). All outcomes were assessed at 90 days of exposure to montelukast. Children who used neuropsychiatric medicine at baseline were excluded in assessment of Outcome 1.

Results: We identified 193,994 children with asthma. No association was found between initiation of montelukast and Outcome 1 or Outcome 2, respectively (HR (95% CI) = 1.08 (0.97-1.18), p=0.18, and HR (95% CI) = 0.92 (0.77-1.10), p=0.36).

Conclusion: Initiating montelukast in children with asthma was not associated with the onset of neuropsychiatric events.
Original languageEnglish
JournalThe European Respiratory Journal
Volume62
Issue numberSuppl 67
Pages (from-to)PA5363
Number of pages1
ISSN0903-1936
DOIs
Publication statusPublished - 2023

Cite this